Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient

Abstract

Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.

The invention claimed is: 
     
       1. A pharmaceutical composition for treating psoriasis comprising:
 a peptide consisting of Arg-Leu-Tyr-Glu (SEQ. ID NO: 1), in which N-terminal L-Arg is acetylated; and 
 a pharmaceutically acceptable carrier. 
 
     
     
       2. A method of treating psoriasis in a subject in need thereof, the method comprising administering a peptide consisting of Arg-Leu-Tyr-Glu (SEQ. ID NO: 1), in which N-terminal L-Arg is acetylated as an active ingredient to the subject. 
     
     
       3. The method of  claim 2 , wherein the peptide is administered in a composition further comprising a pharmaceutically acceptable carrier. 
     
     
       4. A pharmaceutical composition for treating psoriasis comprising:
 a peptide consisting of Arg-Leu-Tyr-Glu (SEQ. ID NO: 6); and 
 a pharmaceutically acceptable carrier. 
 
     
     
       5. A method of treating psoriasis in a subject in need thereof, the method comprising administering a peptide consisting of Arg-Leu-Tyr-Glu (SEQ. ID NO: 6), of  claim 4  as an active ingredient to the subject. 
     
     
       6. The method of  claim 5 , wherein the peptide is administered in a composition further comprising a pharmaceutically acceptable carrier.